Scholarlink

<p>RNA modification recognition proteins are crucial in cancer development and progression. Among all RNA modification-related proteins (RMRPs), Weighted Gene Co-expression Network Analysis (WGCNA), combined with comprehensive bioinformatic analysis, suggests that NAT10—the sole known writer of <i>N</i>4-acetylcytidine (ac4C)—is a critical regulatory protein in colorectal cancer (CRC) progression. NAT10 facilitates the malignancy phenotypes and DNA damage repair in CRC cells via its ac4C transferase activity and regulation of <i>PPAN</i>. Specifically, NAT10 enhances the translation efficiency of <i>PPAN</i> via acetylation at the C744 and C747 sites. In addition, NAT10 promotes the translation of ac4C-modified <i>MYC</i> mRNA. MYC protein then enhances <i>PPAN</i> transcription through binding to the <i>PPAN</i> promoter. The newly identified ac4C reader protein MYBBP1A mediates NAT10-induced translation of both <i>PPAN</i> and <i>MYC</i>. We further found that VDR binds to the <i>NAT10</i> promoter to activate its transcription, resulting in the high expression of NAT10 in CRC. Xenograft studies and clinical data confirmed the role of the NAT10-PPAN axis in promoting CRC development and DNA damage repair. Collectively, our study reveals the role and underlying mechanism of mRNA ac4C modification in CRC progression, providing critical potential targets for CRC drug development.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NAT10 triggers colorectal cancer progression via promoting PPAN-regulated DNA damage repair

  • 期刊论文

  • 发表日期：

    2025年12月27日

查看全文
  • Haoran Wang,
  • Lichen Ge,
  • Jianing Li,
  • Ke Zhong,
  • Shanzhi Li,
  • Ningjing Ma,
  • Lijun Tao,
  • Jiawang Zhou,
  • Zhaotong Wang,
  • Xing Chang,
  • Yunqing Lu,
  • Yalan Rui,
  • Guoyou Xie,
  • Weifeng Yang,
  • Zuanzong Xu,
  • Abdulaziz Ahmed A. Saad,
  • Xiansong Wang,
  • Zhuojia Chen,
  • Wanglin Li,
  • Cheng Yi,
  • Hongsheng Wang,
  • Kun Zhang

摘要

RNA modification recognition proteins are crucial in cancer development and progression. Among all RNA modification-related proteins (RMRPs), Weighted Gene Co-expression Network Analysis (WGCNA), combined with comprehensive bioinformatic analysis, suggests that NAT10—the sole known writer of N4-acetylcytidine (ac4C)—is a critical regulatory protein in colorectal cancer (CRC) progression. NAT10 facilitates the malignancy phenotypes and DNA damage repair in CRC cells via its ac4C transferase activity and regulation of PPAN. Specifically, NAT10 enhances the translation efficiency of PPAN via acetylation at the C744 and C747 sites. In addition, NAT10 promotes the translation of ac4C-modified MYC mRNA. MYC protein then enhances PPAN transcription through binding to the PPAN promoter. The newly identified ac4C reader protein MYBBP1A mediates NAT10-induced translation of both PPAN and MYC. We further found that VDR binds to the NAT10 promoter to activate its transcription, resulting in the high expression of NAT10 in CRC. Xenograft studies and clinical data confirmed the role of the NAT10-PPAN axis in promoting CRC development and DNA damage repair. Collectively, our study reveals the role and underlying mechanism of mRNA ac4C modification in CRC progression, providing critical potential targets for CRC drug development.